Loading...
•
Dec 31, 2025
OmniAb Q4 2025 Earnings Report
OmniAb reported fourth quarter and full year 2025 financial results and business highlights.
Key Takeaways
OmniAb reported a decrease in Q4 revenue to $8.4 million, primarily due to lower license and service revenue, while net loss widened slightly to $14.2 million. Despite the financial decline, the company expanded its partner base to 107 active partners and launched OmniUltra™, a new transgenic chicken technology for antibody discovery.
Q4 revenue decreased to $8.4 million from $10.8 million in the prior year period.
Active partners grew to 107 with a total of 407 active programs as of year-end.
Launched OmniUltra™, a transgenic chicken platform for ultralong CDRH3 domains and picobodies™.
Maintained a solid cash position of $54.0 million in cash, equivalents, and short-term investments.
Revenue by Segment
Forward Guidance
OmniAb expects significant revenue growth in 2026 with a focus on disciplined cost management and advancing partner pipelines.
Positive Outlook
- 2026 revenue guidance of $25 million to $30 million.
- Expected year-end cash balance of $30 million to $35 million.
- Launch of OmniUltra™ expected to attract new partners.
- Strong interest in the xPloration partner access program.
- Several later-stage assets emerging with potential for meaningful milestones.
Challenges Ahead
- Total costs and operating expenses projected between $80 million and $85 million.
- Cash and cash equivalents expected to decrease from current levels by year-end 2026.
- Biopharmaceutical development remains inherently uncertain.
- Reliance on a limited number of third-party manufacturers for xPloration.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...